Tectonic Advisors LLC Increases Stake in Gilead Sciences, Inc. $GILD

Key Points

• Tectonic Advisors LLC has increased its stake in Gilead Sciences by 8.0%, owning 88,326 shares valued at approximately $9.79 million.
• Insider trading activity includes Johanna Mercier selling 28,000 shares for over $3.3 million, reducing her position by 19.70%.
• Gilead Sciences reported Q2 earnings of $2.01 EPS, exceeding estimates, with revenues of $7.08 billion, reflecting a 1.4% year-over-year increase.

Tectonic Advisors LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 88,326 shares of the biopharmaceutical company's stock after buying an additional 6,541 shares during the period. Tectonic Advisors LLC's holdings in Gilead Sciences were worth $9,793,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences during the 1st quarter worth approximately $25,000. Activest Wealth Management increased its stake in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 227 shares during the period. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences during the 1st quarter worth approximately $29,000. Colonial Trust Advisors increased its stake in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 213 shares during the period. Finally, Core Alternative Capital increased its stake in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company's stock, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,000 shares of company stock valued at $9,402,130. Company insiders own 0.27% of the company's stock.

Gilead Sciences Trading Up 1.3%

NASDAQ GILD opened at $118.25 on Thursday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm's fifty day moving average price is $114.48 and its 200 day moving average price is $110.12. The company has a market capitalization of $146.73 billion, a price-to-earnings ratio of 23.56, a price-to-earnings-growth ratio of 0.79 and a beta of 0.34. Gilead Sciences, Inc. has a 12 month low of $84.17 and a 12 month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's revenue was up 1.4% on a year-over-year basis. During the same period last year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Analyst Ratings Changes

Several brokerages recently weighed in on GILD. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Gilead Sciences in a research note on Wednesday. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the company from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Finally, JPMorgan Chase & Co. raised their price target on Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $117.67.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.